A 58-year-old man with a 15-year history of hypertension (BP usually 160–180/100–110 mmHg, on no antihypertensive therapy) presents to the emergency department with sudden-onset severe occipital headache, neck stiffness, and photophobia. His wife reports he was watching television when he suddenly cried out and collapsed. On examination: BP 210/130 mmHg, HR 98/min, GCS 14 (E3V5M6). Fundoscopy shows papilledema. CT head (non-contrast) shows a 4 cm hyperdense lesion in the right basal ganglia with intraventricular extension and mild hydrocephalus. No subarachnoid blood. Which of the following is the most appropriate immediate management?

Explanation

## Clinical Presentation & Diagnosis **Key Point:** This patient has a hypertensive intracerebral hemorrhage (ICH) in the basal ganglia with intraventricular extension and hydrocephalus—a neurosurgical emergency requiring immediate BP management. ## Pathophysiology of ICH Hypertensive ICH occurs when chronic hypertension damages small penetrating arteries (lipohyalinosis), leading to rupture and bleeding into the brain parenchyma. The basal ganglia is the most common site (35–50% of cases), followed by thalamus, pons, and cerebellum [Harrison's Principles of Internal Medicine, 21e, Ch 297]. ## Blood Pressure Management in Acute ICH — Current Guidelines | Principle | Rationale | |-----------|-----------| | **Target SBP <140 mmHg** | Reduces hematoma expansion; supported by INTERACT2 and ATACH-2 trials | | **Preferred agents: IV labetalol or nicardipine** | Titratable, short-acting, predictable effect; recommended by AHA/ASA 2022 guidelines | | **Avoid nitroprusside** | Causes reflex tachycardia, unpredictable BP swings, cyanide toxicity risk | | **Avoid hydralazine** | Unpredictable, prolonged effect; not recommended as first-line in acute ICH | | **Avoid withholding treatment** | Uncontrolled hypertension drives hematoma expansion in the first 3–6 hours | **High-Yield:** The **INTERACT2 trial (2013)** and **AHA/ASA 2022 ICH Guidelines** recommend that for patients with acute ICH and SBP 150–220 mmHg, rapid reduction of SBP to **<140 mmHg** using IV labetalol or nicardipine is safe and improves 90-day functional outcomes by limiting hematoma expansion. This is the current standard of care. ## Why Option A (Correct) is Optimal 1. **Target <140/90 mmHg** aligns with AHA/ASA 2022 and INTERACT2 evidence for acute ICH with SBP >150 mmHg. 2. **IV labetalol or nicardipine** are the guideline-recommended first-line agents — titratable, short-acting, and safe in ICH. 3. **Rapid but controlled reduction** within the first hour limits the "golden window" of hematoma expansion (first 3–6 hours). 4. This patient's SBP (~210 mmHg) is well above 150 mmHg, making active treatment clearly indicated. ## Why Other Options Are Incorrect - **Option B:** Withholding antihypertensives until ICP monitoring is established is inappropriate; uncontrolled hypertension drives hematoma expansion and worsening outcomes. - **Option C:** A MAP reduction of only 10–20% in the first hour is too conservative per current guidelines, and **hydralazine is NOT a recommended first-line agent** for acute ICH due to its unpredictable, prolonged vasodilatory effect. - **Option D:** Targeting <120/80 mmHg with nitroprusside is excessively aggressive; ATACH-2 showed that targeting SBP <120 mmHg did not improve outcomes and increased renal adverse events. Nitroprusside also carries risks of reflex tachycardia and cyanide toxicity. ## Additional Management - **Urgent neurosurgery consultation** for possible external ventricular drain (EVD) placement due to intraventricular extension and hydrocephalus. - **Coagulopathy reversal** if patient is on anticoagulants or antiplatelet agents. - **Osmotic therapy** (mannitol or hypertonic saline) if signs of herniation. - **Temperature control, seizure prophylaxis, DVT prophylaxis.** **Clinical Pearl:** Per AHA/ASA 2022 guidelines, for acute ICH with SBP 150–220 mmHg, rapid reduction to SBP <140 mmHg using IV labetalol or nicardipine is recommended (Class IIa, Level A). Hydralazine and nitroprusside are NOT preferred agents due to unpredictable pharmacokinetics and adverse effect profiles.